Title: A multivalent RSV vaccine based on the Modified Vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a Phase 3 clinical study

ABSTRACT

Respiratory syncytial virus (RSV) causes a significant disease burden in older adults. The live recombinant vaccine based on a nonreplicating modified vaccinia Ankara (MVA-BN) poxvirus, MVA-BN-RSV, encoding for multiple proteins of RSV subtypes A and B, was assessed for efficacy against respiratory disease caused by RSV.

Adults aged ≥ 60 years, with or without underlying chronic conditions, were enrolled and randomized in a 1:1 ratio to receive a single dose of vaccine or placebo and were followed for disease caused by RSV infection during the 2022-2023 season. The 2 primary endpoints were RSV-associated lower respiratory tract disease (LRTD) with ≥ 3 and ≥ 2 symptoms; acute respiratory disease (ARD) was a key secondary endpoint. The humoral RSV-specific immune response was assessed at baseline and 14 days post-vaccination. Safety was evaluated by collection of solicited adverse events (AEs) and unsolicited AEs for 7 and 28 days post-vaccination respectively, and SAEs for the entire study period.

In total, 18348 participants were included in the final efficacy and safety analyses. Vaccine efficacy was 42.9% (95% CI: -16.1; 71.9) against RSV-associated LRTD with \geq 3 symptoms, 59.0% (95% CI: 34.7; 74.3) against LRTD with \geq 2 symptoms, and 48.8% (95% CI: 25.8; 64.7) against ARD. The primary objective was not met for LRTD with \geq 3 symptoms since the lower bound of the 95% CI was below 20%, the prespecified success criterion. The vaccine-elicited immune response showed mean fold-increases of 1.7 for RSV A and B neutralizing antibodies and 2.9 and 4.3 for RSV-specific IgG and IgA, respectively. The vaccine displayed mild to moderate reactogenicity, and no safety concerns were identified. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

MVA-BN-RSV induced suboptimal protection against RSV-associated LRTD, likely due to suboptimal neutralizing antibody response. The vaccine had an acceptable safety profile and confirmed immunogenicity, overall showing promise for MVA-BN-vectored constructs targeting other diseases.

Trial Registration: Clinicaltrials.gov Identifier NCT05238025 (Registered February 14,

2022).

Keywords: RSV, respiratory syncytial virus, vaccine, MVA-BN-RSV, MVA-BN, efficacy, safety, older adults, modified vaccinia virus Ankara.

Title: A multivalent RSV vaccine based on the Modified Vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a Phase 3 clinical study

Authors: Elke Jordan^a, Victoria Jenkins^c, Günter Silbernagl^a, Maria Paulina Velasco Chávez^a,

Darja Schmidt^a, Frauke Schnorfeil^a, Stephanie Schultz^a, Liddy Chen^b, Fernanda Salgado^c,

Jeanne-Marie Jacquet^c, Tobias Welte^{d*}, Laurence De Moerlooze^c

^a Bavarian Nordic, Bavarian Nordic GmbH, Martinsried, Germany,

^b Bavarian Nordic Inc., Durham, North Carolina, USA

^c Bavarian Nordic, Bavarian Nordic Switzerland AG, Zug, Switzerland

^d Medizinische Hochschule Hannover. Klinik für Pneumologie und Infektiologie

Carl-Neuberg-Straße 1, 30625 Hannover, Germany

*Dr Tobias Welte was the principal investigator of this clinical study. He passed away on 10

March 2024 before the finalization of this publication. We are grateful for his contribution.

Corresponding author:

Elke Jordan, PhD, Bavarian Nordic GmbH, Fraunhoferstrasse 13, 82152

Martinsried, Germany (Elke.Jordan@bavarian-nordic.com)

Manuscript, ethnia freedince and the presented dely 32/2004. The conversions below in the presented dely 32/2004. The conversions below in the presented dely 32/2004. The conversions below in the presented of the presented dely 32/2004. The conversions below in the presented of the presented dely 32/2004. The

Title: A multivalent RSV vaccine based on the Modified Vaccinia Ankara vector shows
 moderate protection against disease caused by RSV in older adults in a Phase 3 clinical
 study

4 1. Introduction

Respiratory Syncytial Virus (RSV) is a cause of severe respiratory disease in children
below the age of 5 years, where the highest disease burden is observed, but also in older
adults, and adults with underlying comorbidities [1]. Meta analyses estimate the yearly global
incidence of RSV-acute respiratory infection (ARI) to be 6.7 per 1000 adults ≥ 65 years of
age worldwide [2], and 16.2 per 1000 adults ≥ 60 years of age in high income countries [3].
The associated estimated hospitalization rates are 1.0 per 1000 and 1.5 per 1000, respectively
[2, 3].

In the long search for an RSV vaccine, the F protein was recognized as an important 12 antigen able to elicit a protective humoral immune response, and the preF conformation of 13 the protein was identified as the target of naturally induced antibodies during RSV infection 14 [4]. Recent RSV vaccine candidates have used the preF protein as the vaccine antigen in 15 varied approaches: protein, mRNA or vector based [5]. Two vaccines became available in 16 2023 for the immunization of adults from the age of 60 years [6, 7]; both are protein-based 17 and use the RSV F protein, stabilized in its preF conformation. These vaccines elicit a high 18 neutralizing antibody response and have shown a protective efficacy for one RSV season of 19 20 more than 80% in adults \geq 60 years against RSV-associated lower respiratory tract disease (LRTD) [8, 9] and up to 94.1% against severe disease [8]. Data available beyond the initial 21 analysis, for a longer follow-up, reveal variable durability of efficacy according to the 22 platform. A drop in efficacy against RSV-associated LRTD was already visible from 82.4% to 23 63.0% from 3.7 to 8.6 months of follow-up in one RSV season for an mRNA vaccine [10, 24 11]; a decrease in efficacy was visible in the second RSV season for the available protein-25

26 based vaccines [12, 13] with an approximate drop of -10% to -30%, depending on the study and the LRTD endpoint; while for an adenovirus-vectored vaccine, sustained protection 27 against RSV-associated LRTD was observed in a third season of follow-up in phase 2 (78.7% 28 29 in season 3 versus 80.% in season 1) [14, 15], and no evidence of a decline in a second season compared to season 1 was apparent in phase 3 [16]. 30 31 The MVA-BN-RSV vaccine candidate was developed as an alternative, multiple antigen approach, using the modified vaccinia Ankara (MVA-BN) poxvirus as a vector to express 5 32 RSV proteins: the F protein, which is expressed both in the preF and postF conformations, 33 34 the G protein of RSV types A and B, and the internal M2-1 and N proteins [15]. The potential advantages of a multi-component vaccine, i.e. the induction of CD4+ and CD8+ T cell 35 responses, along with antibodies including IgAs, were demonstrated in preclinical studies 36 37 [17]. The immunogenicity profile of MVA-BN-RSV was characterized in Phase 1 and 2 clinical studies. The vaccine elicited RSV-specific IgG and IgA and a neutralizing response 38 against both RSV A and B subtypes [18, 19]. This was accompanied by broad T cell 39 40 responses as measured against 5 peptide pools representing the 5 encoded antigens [18, 19]; fold-increases in T cell responses appeared higher than the F-specific response reported for 41 42 preF focused vaccines [16]. This distinctive balance of humoral responses and strong cellular responses stimulated by multiple antigens was thought to contribute to different pathways of 43 44 protection [16] and suggested potential for a multi-faceted mode of action. MVA-BN-RSV 45 was subsequently shown to prevent RSV colonization in an RSV challenge trial [20]. The Phase 3 study reported here aimed to assess the protective efficacy of the vaccine against 46 LRTD associated with RSV in adults ≥ 60 years of age. 47

48 2. Methods

49 2.1. Study design, population, and vaccination

50 This was a randomized, double-blind, multicenter, placebo-controlled phase 3 study in 51 adults > 60 years of age, which was conducted at over 100 sites in the US and Germany between April 2022 and September 2023. Independent ethics committees or institutional 52 53 review boards for each trial site approved the study protocol and its amendments. All study participants were apprised of the trial aspects and signed an informed consent 54 before any study procedure. The study was conducted according to the ethical principles of 55 the Declaration of Helsinki [21], and Good Clinical Practice guidelines [22] and the 56 applicable regulatory requirements. Safety during the trial was monitored by an Independent 57 58 Data Monitoring Committee, which reviewed unblinded safety data at regular intervals. Study participants were randomly assigned in a 1:1 ratio to 2 groups to receive a single 59 dose of MVA-BN-RSV or placebo, administered intramuscularly in the deltoid muscle. 60 61 Participants could have one or more, clinically stable, chronic medical conditions such as 62 chronic cardiac disease and chronic lung disease, congestive heart failure, hypertension, type 2 diabetes mellitus, hyperlipoproteinemia, or hypothyroidism. Frailty was assessed for each 63 64 participant using the Tilburg frailty indicator. Previous vaccination with an RSV vaccine, or any planned vaccination with an RSV vaccine other than the trial vaccine was an exclusion 65 criterion. 66 MVA-BN-RSV consists of MVA-BN [23] encoding 5 codon optimized RSV antigens: F 67 (subtype A, strain A long), G (subtype A, strain A2), G (subtype B, strain 185 37), N, and 68

69 M2-1 (both strain A2). MVA-BN-RSV and placebo were supplied by Bavarian Nordic A/S,

70 Denmark. MVA-BN-RSV was provided as a liquid frozen formulation containing at least $3 \times$

 10^8 infectious units per 0.5 mL and placebo consisted of Tris-buffered saline.

72 2.2. Objectives

The primary objective of the study was to assess the clinical efficacy of the MVA-BNRSV vaccine against LRTD associated with RSV in adults ≥ 60 years of age, during one RSV

75 season. Two primary endpoints were defined: RSV-associated LRTD with at least 3 76 symptoms and RSV-associated LRTD with at least 2 symptoms; vaccine efficacy (VE) was assessed for endpoints reported from 14 days post-vaccination until the end of one RSV 77 78 season. A key secondary objective was to assess VE against RSV-associated ARD during one 79 RSV season. The assessment of VE against severe LRTD was also a secondary objective, and the assessment of VE against hospitalization or mortality related to confirmed RSV disease 80 was an exploratory objective. A supplementary analysis of VE according to RSV subtype was 81 82 performed, and subgroup analyses of efficacy according to age, sex, race, frailty, pre-existing 83 chronic conditions and region were conducted. Reactogenicity, safety and immunogenicity were assessed as secondary objectives. 84

85 *2.3. Efficacy assessments*

Participants were followed for disease surveillance via monthly telephone calls and
electronic alerts 3 times a week until the end of the RSV season. The occurrence of
respiratory tract symptoms led to a visit at the study site to confirm symptoms and to collect a
nasopharyngeal swab within 5 days of symptom onset for polymerase chain reaction (PCR)
testing at the central laboratory.

91 RSV-associated ARD was defined by the presence of either 1 ARD symptom lasting for at least 24 hours or 2 simultaneously occurring ARD symptoms (irrespective of duration), 92 with onset at least 14 days following vaccination until the end of one RSV season, with RSV-93 association confirmed by PCR. ARD symptoms included: rhinorrhea, nasal congestion, 94 pharyngitis, earache, new cough or worsening of pre-existing cough, new wheezing or 95 worsening of pre-existing wheezing, new sputum production or worsening of pre-existing 96 sputum production, new shortness of breath or worsening of pre-existing shortness of breath, 97 fever > 100°F / > 37.8°C (oral temperature). RSV-associated LRTD was defined as i) severe 98 LRTD, i.e. the presence of at least 1 of the following signs: hypoxemia (oxygen saturation < 99

100 92% at rest in conjunction with an at least 3% decrease from baseline), respiratory rate > 25breaths/Min, imaging evidence of new onset of bronchitis, bronchiolitis, or pneumonia, or ii) 101 LRTD with at least 3 or at least 2 of the following symptoms: new wheezing or worsening of 102 103 pre-existing wheezing, new shortness of breath or worsening of pre-existing shortness of breath, new cough or worsening of pre-existing cough, new sputum production or worsening 104 105 of pre-existing sputum productions, signs of severe LRTD. All documented respiratory tract symptoms with PCR-confirmed RSV positivity were adjudicated to be either ARD, LRTD 106 107 (severe, with 3-symptoms, or with 2-symptoms) or no endpoint by an independent 108 adjudication committee. Study participants were also asked to complete the Respiratory Intensity and Impact 109 Questionnaire (RiiQ) [24] to assess changes in symptoms after RSV symptom onset until 110 111 symptoms resolved or until 21 days. Symptoms were self-reported based on a grading scale: none, mild, moderate, severe. 112 2.4. Immunogenicity assessments 113 Serum antibody responses were assessed in a subset of approximately 600 participants, 114 from whom blood samples were collected at study entry and 14 days post-vaccination. 115

116 Antibody responses elicited by MVA-BN-RSV were measured using RSV-specific

117 immunoglobulin (Ig) G enzyme linked immunosorbent assay (ELISA), IgA ELISA and

118 plaque reduction neutralization test for RSV subtype A and subtype B, as described earlier

119 [19]. Serum assays were performed at Bavarian Nordic GmbH, Martinsried, Germany.

120 2.5. Safety assessments

Local and systemic solicited adverse events (AEs) were assessed for 7 days after
vaccination, unsolicited AEs were monitored for 28 days post vaccination and beyond if
ongoing. Information on SAEs was collected throughout the study. Vital signs (peripheral

124 oxygen saturation, respiratory rate, blood pressure, pulse rate and body temperature) were
125 assessed at on-site study visits. AEs were graded in intensity using the FDA Toxicity Grading
126 Scale for Healthy Adult and Adolescent Volunteers Enrolled in preventive Vaccine Clinical
127 Trials [25].

128 2.6. Statistical methods

The sample size was calculated based on an expected VE of 80% for RSV-associated 129 LRTD with \geq 3 symptoms, and of 65% for LRTD with \geq 2 symptoms. Assuming an incidence 130 rate of 0.2% for LRTD with \geq 3 symptoms, and 0.4% for LRTD with \geq 2 symptoms, in the 131 placebo group during one RSV season, approximately 20,000 participants vaccinated in the 2 132 treatment groups allowed the observation of at least 22 cases of LRTD with \geq 3 symptoms 133 and 53 cases of LRTD with ≥ 2 symptoms, providing at least 90% and 85% power, 134 135 respectively. A hierarchical testing strategy was employed. Endpoints were to be tested sequentially 136 against the null hypothesis of VE $\leq 20\%$ at the 2-sided significance level α =0.05, i.e. the 137 lower bound of the 2-sided confidence interval (CI) around the estimate of VE was to be 138

139 greater than 20% to meet the objective for the respective endpoint.

140 The full analysis set (FAS) was the primary analysis set for efficacy assessments; it 141 consisted of participants who were randomized to any treatment arm and received the study 142 vaccination. The safety set (SS) was the primary analysis set for safety evaluation; it included 143 participants who received any MVA-BN-RSV vaccine or placebo.

During the study, multiple enrollers were identified through monitoring visits based on similarities in participants details. A systematic verification of all study participants was then performed with support from the vendor who processed participant compensation fees. In total, 826 participants were identified as having been enrolled and vaccinated more than one time in the trial, at different sites located mostly within a 30-mile distance. These participants

had received multiple doses of MVA-BN-RSV or placebo (in total 1824 vaccinations). These
multiple enrollers were included in the FAS for the primary efficacy analysis with group
allocation based on the first treatment received (MVA-BN-RSV or placebo) and with data
censored from the time of second vaccination. Multiple enrollers were included in the safety
set for safety analysis, with participants having received the MVA-BN-RSV vaccine at least
once analyzed in the MVA-BN-RSV group, and those who had only received placebo
analyzed in the placebo group.

For the primary analysis, VE against LRTD was defined as the relative reduction in the 156 157 hazard rate of LRTD associated with RSV in the MVA-BN-RSV vaccinated group compared with that in the placebo group. For each of the 2 primary endpoints, a Cox proportional 158 159 hazards regression model based on the FAS, stratified by age group, was used as the primary 160 analysis to establish VE against LRTD. The follow-up time for participants who developed LRTD associated with RSV was defined as (first LRTD onset date minus vaccination date 161 plus 1), and LRTD onset was defined as the date when the first LRTD symptoms were 162 observed, with the sample obtained at the related on-site visit being positive for RSV by 163 PCR. Participants who did not develop any LRTD event were censored at time of dropout or 164 at the end date of the RSV season. The same approach was adopted for the analysis of the key 165 secondary endpoint (ARD associated with RSV). 166

Post-hoc analyses were performed based on self-reported symptoms in the RiiQ. In the RiiQ, 4 symptoms (coughing, wheezing, shortness of breath and sputum production) constituted the Lower Respiratory Symptoms domain. Based on self-reported symptoms for participants with PCR-confirmed RSV disease, VE against LRTD with at least 2 or 3 selfreported symptoms among the 4 listed, was calculated. In addition, the area under the curve (AUC) of the change from baseline in the RiiQ total score (defined as the mean of the 3

domain scores) and the mean duration of any symptoms were calculated for the 2 treatmentgroups.

175Descriptive summaries per group were provided for local and systemic solicited AEs176with any intensity and per intensity grade; unsolicited AEs, including any intensity, grade ≥ 3 177and related events classified according to the Medical Dictionary for Regulatory Activities178(MedDRA); SAEs and related SAEs.

179RSV subtype A and B neutralizing serum activity and RSV-specific IgG, IgA antibody

titers at baseline and 14 days post-vaccination were summarized descriptively by treatment

181 group. Geometric mean titers (GMT) and geometric mean fold-increases (GMFI) from

baseline were calculated with 95% CIs for all immunogenicity endpoints.

183 **3. Results**

184 *3.1. Study population*

A total of 18348 participants were enrolled and vaccinated; multiple enrollers were counted once. Overall, 826 participants were identified as multiple enrollers. These participants were handled appropriately during analyses and consequently did not affect the reported results. A limited number of participants were identified by study sites as having participated in another RSV clinical trial. These participants were excluded from efficacy analyses. The resulting FAS and SS are described in Figure 1.

191 The demographic characteristics of participants were similar in the 2 groups (Table 1).

192 Their mean age was 70.4 years, more than 4000 (22.5%) were \geq 75 years of age, 66.5% had

underlying chronic lung or cardiac diseases putting them at higher risk of severe RSV disease

and 10.7% were frail. Overall, 13.0% of study participants were Black or African American

and 28.7% were Hispanic or Latino.

196 *3.2. Efficacy*

197 The assumption used for sample size calculation of a 0.2% incidence for LRTD with ≥ 3 symptoms during one RSV season was confirmed since 21 cases were reported for 9188 198 placebo recipients (0.23%) during the RSV season. The cut-off date for the analysis of 199 200 efficacy was 6 March 2023, at which time, the RSV season was considered over based on country-specific surveillance data [26, 27]. The number of LRTD events accrued by that time 201 202 was above the number required by the sample size estimation. There were 12 reports of RSV-associated LRTD with \geq 3 symptoms in the MVA-BN-203 RSV group and 21 in the placebo group, giving a VE of 42.9% (95% CI: -16.1; 71.9) (Figure 204 205 2A). For this primary endpoint, the study failed to meet the success criterion of a lower bound of the 95% CI greater than 20%. There were 25 reports of RSV-associated LRTD with ≥ 2 206 207 symptoms in the MVA-BN-RSV group and 61 in the placebo group, for a VE of 59.0% (95% 208 CI: 34.7; 74.3) (Figure 2B). For RSV-associated ARD, VE was 48.8% (95% CI: 25.8; 64.7) with 42 reports in the MVA-BN-RSV group and 82 in the placebo group (Figure 3C). For 209 LRTD with ≥ 2 symptoms and ARD, the lower bound of the 95% CI was above 20%. Per the 210 planned hierarchical testing strategy, no formal conclusion can be drawn for these 2 211 endpoints, although positive efficacy was observed. 212 There were no hospitalizations due to RSV-associated disease during the study. There 213 were 2 cases of RSV-associated LRTD that met the definition of severe disease, both in the 214 placebo group. One had a respiratory rate > 25 breaths/Min and one had imaging evidence of 215 new onset of pneumonia. 216

The exploratory analysis of vaccine efficacy based on the number and intensity of symptoms self-reported by participants in the RiiQ confirmed a moderate efficacy against RSV-associated LRTD, which ranged from 58.1% (95% CI: 36.3; 72.5) to 77.8% (95% CI: 56.0; 88.8), depending on the number and severity of reported symptoms (Supplementary Table 1). The analysis of the severity of symptoms of RSV-associated disease based on the

222	RiiQ showed that RSV-associated LRTD was milder in RSV vaccine recipients who
223	experienced breakthrough disease (Figure 3). The median duration of symptoms was also
224	lower in the RSV-MVA-BN group (11.5 days) than in the placebo group (15 days).
225	Subgroup analyses were consistent with the findings of the primary efficacy analysis
226	(data on file), except for the analysis per sex, which showed higher VE estimates in females
227	compared to males, for the primary and key secondary RSV disease endpoints
228	(Supplementary Table 2). However, while VE was substantially higher in female participants
229	compared to male participants in the subset with exactly 1 symptom and the subset with 3 or
230	more symptoms, it was almost the same in the subset with exactly 2 symptoms: 69.7% (95%
231	CI: 24.5; 87.8) in females versus 65.3% (95% CI: 18.0; 85.3) in males (Supplementary Table
232	3).

233 *3.3. Immunogenicity*

MVA-BN-RSV induced a humoral immune response in terms of neutralizing antibodies against the 2 RSV subtypes, and of RSV-specific IgG and IgA (Table 2). Fourteen days after RSV-MVA-BN vaccination, GMFIs were 1.7 for RSV A and RSV B neutralizing antibody titers, and 2.9 and 4.3 for IgG and IgA antibody titers, respectively. The analysis of immune responses per sex (Supplementary Table 4) showed slightly higher baseline titers and slightly lower fold increases in males for all immunogenicity measurements.

240 *3.4. Reactogenicity and safety*

The most frequent solicited AEs, reported by more than 30% of vaccinees, were pain at the injection site, myalgia, fatigue, and headache (Figure 4). Grade 3 solicited local AEs were reported by 4.6% of MVA-BN-RSV vaccinees, and grade \geq 3 systemic AEs by 4.5% of vaccine recipients. A similar proportion of participants (6.5%) in the 2 groups reported unsolicited AEs during the 28 days following vaccination (Table 3); and during that same

period, 1.1% participants in the MVA-BN-RSV group compared to 0.6% in the placebo group reported related unsolicited AEs. The reported unsolicited AEs were generally mild (Grade 1) and self-limited. Grade \geq 3 unsolicited AEs assessed as related to study intervention were consistent with the solicited AEs reported following vaccination by participants. Vital sign monitoring did not detect any physical findings of concern.

251 SAEs collected during the entire study period were reported with similar frequencies in the 2 study groups: 5.5% and 4.7% in the MVA-BN-RSV group and in placebo group, 252 respectively. SAEs considered to be related to the study vaccination (possibly, probably, or 253 254 definitely related to study vaccination) occurred in 7 participants, (0.1%, 10 events) in the MVA-BN-RSV group, and in 5 participants (0.1%, 5 events) in the placebo group. In both 255 groups, 1 event each of atrial fibrillation and pneumonia was reported. In the MVA-BN-RSV 256 257 group, there were also 2 events of cerebrovascular accident, 2 events of syncope, 1 event of an altered state of consciousness, 1 event of pyrexia, and 1 participant presented the events of 258 injection site erythema and pruritus. In the placebo group, in addition, 1 event each of colitis, 259 wheezing, and thrombosis occurred. No fatal cases were considered to be related to the study 260 vaccination. A total of 75 participants died during the study: 41 (0.4%) in the MVA-BN-RSV 261 262 group and 34 (0.4%) in the placebo group. The most frequently reported fatal SAE by System Organ Class was cardiac disorder in the 2 study groups. The causes of death reported among 263 264 study participants were representative of the most common causes of death in the elderly 265 adult population and, considering that these fatal events were more likely attributable to the participant's underlying risk factors (e.g. diabetes mellitus type 2, hypertension), none of the 266 fatal events was considered by the study investigator to be related to study vaccination. The 267 268 safety information was continuously presented to the Data Monitoring Committee and no concern was raised after review and assessment. 269

270 4. Discussion

- This study was undertaken to assess the efficacy of the MVA-BN-RSV vaccine against
 RSV-associated ARD and LRTD in adults ≥ 60 years of age.
- 273 The study population was reflective of the general population of older adults targeted for
- 274 RSV vaccination, as more than 4000 participants were \geq 75 years of age, a majority had
- underlying cardiac or respiratory conditions and 10.7% were frail. The study population
- 276 reasonably reflected racial and ethnic diversity in the study locations and was well balanced
- 277 for sex and other demographic characteristics across the two groups.

278 VE against LRTD with at least 3 symptoms was 42.9% (95% CI: -16.1; 71.9) and the predefined success criterion of a CI lower bound greater than 20% was not met. Given this, 279 280 per the hierarchical testing strategy adopted, no formal conclusion on efficacy relating to the 281 endpoints tested next in the sequence can be made. The results of the analyses for VE against 282 RSV-associated LRTD with at least 2 symptoms and against ARD showed estimates of 59.0% and 48.8% respectively with lower bounds above 20%, and are consistent with a positive, 283 284 although suboptimal, protection against RSV disease. The analysis of the patient-reported outcomes through the RiiQ also confirmed the presence of efficacy against RSV-associated 285 disease, with moderate estimates that were in line with those reported in the primary analysis 286 for LRTD with at least 2 symptoms. The fact that the patient-reported severity and duration of 287 symptoms were lower in breakthrough cases in the vaccine group than in the placebo group 288 289 also supports the fact that the vaccine conferred some protection against RSV-associated disease, although not to the expected level. 290

Subgroup analyses of VE for each of the disease endpoints per age, sex, race, underlying
chronic conditions, and geographic regions were performed (data on file). These analyses
were generally consistent with the primary analyses, except for the per sex analysis, which
showed higher VE estimates in females. The vaccine immunogenicity measured in this study

295 was in line with Phase 1 and 2 assessments, showing comparable fold-increases and postvaccination titers in the two sexes [18, 19]. In this study, the analysis of immunogenicity per 296 sex did not reveal major differences between males and females, although slightly higher 297 298 baseline levels, and thus slightly lower fold increases, were seen in males. Also, in earlier studies [18, 19], cellular responses analyzed per sex showed similar values and fold-increases 299 in males and females (data on file). Other efficacy studies of RSV vaccines did not report a 300 higher efficacy in females [10, 28, 29], and the difference in VE across sexes observed in this 301 trial was not expected. In view of the similar immunogenicity and baseline characteristics in 302 303 males and females (data on file), we have not found an explanation, nor a plausible physiological mechanism for a differential efficacy per sex for this vaccine. Generally, 304 305 females, including elderly women, usually mount a higher immune response to vaccines than 306 males, and vaccine efficacy in females tends to be higher regardless of age or vaccine [30]. A study evaluating sex effect in influenza vaccine effectiveness showed a 19% (48% for 307 females and 29% for males, p = 0.03) difference in adults ≥ 50 years [31], although vaccine 308 309 efficacy is generally not considered different between females and males for available influenza vaccines. A review article investigating sex differences in respiratory viral 310 pathogenesis of disease revealed males to be more susceptible than females to severe 311 outcomes from respiratory viral infections at younger and older ages in general, but no sex 312 specific data was found for RSV-associated disease in older adults [32]. 313 314 Given that VE was substantially higher in females than in males for the subset with ≥ 3 symptoms, it may be possible that MVA-BN-RSV, a unique vaccine that expresses 5 RSV 315 proteins, proved more effective in females in preventing more severe disease, which would be 316 corroborated by the fact that, for LRTD with exactly 2 symptoms, VE was similar (65-70%) 317 in the two sexes. However, VE was also higher in females compared to males for the mild 318 disease subset (i.e. with ≤ 1 symptom), which does not validate the view that the sex 319

difference would be limited to more severe disease. Due to the small number of cases in
subgroups and the lack of identified biological plausibility, we cannot preclude the influence
of other random factors.

In our study, only 2 cases of RSV-associated disease with complications or of high severity were reported, both in the placebo group; due to the low number of cases, this does not inform on the level of protection that MVA-BN-RSV could afford against severe RSV disease.

Before initiating vaccine efficacy evaluation in this Phase 3 study, the ability of MVA-327 BN-RSV to prevent RSV infection and colonization was assessed in an RSV challenge trial, 328 where MVA-BN-RSV vaccination was effective at reducing the RSV viral load, the number 329 of RSV infections and symptoms after challenge [20], and vaccine efficacy against RSV-330 confirmed, symptomatic infection was 79.3% to 88.5%. These values were not reproduced in 331 the efficacy study reported here. The RSV controlled human challenge trials have inherent 332 limitations due to the use of highly attenuated RSV strains causing mild to moderate upper 333 respiratory tract disease; such studies can reveal the protective potential of a vaccine, though 334 their results cannot be directly reflective of larger vaccine efficacy studies or real-world 335 analysis [33]. The results of the MVA-BN-RSV challenge trial are nevertheless coherent with 336 the efficacy estimated against ARD and milder LRTD with at least 2 symptoms, but do not 337 338 align with the efficacy seen against more severe LRTD.

The adopted vaccine approach proved unable to afford the pursued high level of protection despite the strong and diverse T cell response elicited, which, given the recognized importance of T cell responses for protection against RSV symptomatic infection [34], had given confidence in the multi antigen approach. This broad T cell response was not capable of counterbalancing a lower neutralizing antibody response, confirming the importance of a high neutralizing antibody response and preF focus for optimal protection against RSV. Indeed, the

345 humoral immune response elicited by MVA-BN-RSV was lower than that elicited by preFfocused vaccines. Although assays are different and values not directly comparable, the fold-346 increases from baseline (1.7 for neutralizing antibodies and 2.9 for IgG) were lower than 347 348 those described for preF-based vaccines, which ranged 8-12 for neutralizing antibodies [8, 14, 35] and 8-13 for IgG [8, 14]. The efficacy observed for MVA-BN-RSV, was suboptimal 349 but was higher than that reported with two postF-based vaccines. These showed no efficacy 350 in Phase 3: one displayed a VE of -7.1% (90% CI: -106.9; 44.3) against RSV-associated acute 351 respiratory infection [36], and the other VEs of -7.9% (unspecified% CI: -8; 37) against RSV-352 353 associated moderate-severe LRTD, and 12.6% (unspecified% CI: -14; 33) against ARD [37]. This is in contrast with the preF-focused vaccines, which all showed high efficacy in the 354 initial first RSV season evaluation regardless of the platform [8, 9, 10, 14]. MVA-BN-RSV, 355 356 which induces a mixed pre- and post-fusion expression of the RSV F protein, therefore appears to confer an intermediate efficacy between that afforded by the postF-based and the 357 preF-based vaccines. 358

From an operational point of view, although the presence of participants who had enrolled more than once and had received multiple vaccinations had no bearing on the analysis, thanks to early detection and appropriate handling, the issue of multiple enrollers in clinical studies is of concern, as this has potential to impair results, and should be a point of attention in the conduct of trials.

The evaluation of MVA-BN-RSV in more than 9000 older individuals in this study confirmed the mild to moderate reactogenicity profile of the vaccine. A similar number of adverse events were observed among the 2 study groups and no safety concern was identified by the Data Monitoring Committee. These data are in line with those obtained with the MVA-BN poxvirus vaccine Jynneos® [38]. In all completed clinical trials, vaccinations with MVA-BN or MVA-BN-based vaccines displayed a good safety profile and were well tolerated in all

370	the pop	pulations of healthy, elderly or immunocompromised individuals assessed. A recent
371	meta-a	nalysis encompassing 8 clinical studies with MVA-BN, of which 6 were placebo-
372	contro	lled, showed that, following a single dose of MVA-BN, no difference with placebo was
373	demon	strated for the outcomes of SAEs, AEs of special interest or AEs requiring
374	discon	tinuation [39].
375	5 Co	onclusions
575	J. CU	
376	The M	VA-BN-RSV vaccine demonstrated suboptimal efficacy against RSV-associated
377	LRTD	, in this double-blind placebo-controlled randomized trialAlthough efficacy against
378	the first	st primary endpoint was not met, the vaccine displayed some, moderate protective
379	efficac	y against RSV-associated LRTD and ARD. The immunogenicity of the vaccine was
380	also es	tablished, confirming that MVA-BN can be used as a vector platform, to build safe and
381	effecti	ve vaccines based on adequate constructs. This large trial also confirmed the safety of
382	the MV	VA-BN platform as a vector, including in an older population with co-morbidities.
383	All aut	thors attest they meet the ICMJE criteria for authorship.
384	Refere	ences
385	1.	Piralla A, Chen Z, Zaraket H. An update on respiratory syncytial virus. MC Infectious
386		Diseases (2023) 23:734.
387	2.	Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X, Campbell H, Demont,
388		Nyawanda BO. Chu HY et al. Global Disease Burden Estimates of Respiratory
389		Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A
390		Systematic Review and Meta-Analysist al. The Journal of Infectious Disease,
391		2020;222(S7):S577–83
392	3.	Savic M, Penders Y, Shi T, Branche A, Pirçon JY. Respiratory syncytial virus disease
393		burden in adults aged 60 years and older in high-income countries: A systematic

394		literature review and meta-analysis. Influenza Other Respi Viruses. 2023;17:e13031.
395		https://doi.org/10.1111/irv.13031
396	4.	Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, Buchholz
397		UJ, Openshaw PJ, McLellan JS, Englund JA et al. The respiratory syncytial virus
398		vaccine landscape: lessons from the graveyard and promising candidates. Lancet
399		Infect Dis. 2018 Oct;18(10):e295-e311. doi: 10.1016/S1473-3099(18)30292-5 Epub
400		2018 Jun 18
401	5.	Topalidou X, Kalergis AM, Papazisis G. Respiratory Syncytial Virus Vaccines: A
402		Review of the Candidates and the Approved Vaccines. Pathogens 2023, 12, 1259.
403		https://doi.org/10.3390/pathogens12101259
404	6.	US Food and Drug Administration, Abrysvo® package insert. Available at
405		https://www.fda.gov/vaccines-blood-biologics/abrysvo
406	7.	US Food and Drug Administration, Arexvy® package insert. Available
407		at https://www.fda.gov/vaccines-blood-biologics/arexvy
408	8.	Papi A, Ison MG, Langley JM, Lee D-M, Leroux-Roels I, Martinon-Torres F et al.
409		Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J
410		Med 2023;388:595-608. DOI: 10.1056/NEJMoa2209604
411	9.	Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M et al. 2023
412		Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N Engl J
413		Med 2023;388:1465-77. DOI: 10.1056/NEJMoa2213836
414	10	. Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K et al. Efficacy
415		and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. N Engl J Med
416		2023;389:2233-44.DOI: 10.1056/NEJMoa2307079
417	11	. Wilson E, Goswami J, Doreski PA, Perez-Marc G, Jimenez G, Priddy F, Lin N, Le
418		Cam N, Slobod K, Stoszek SK et al. Efficacy and Safety of mRNA-1345, an RSV

419		Vaccine, in Older Adults: Results through ≥ 6 Months of Follow-up. RSVVW
420		ReSVINET Conference February 13-16 2024, Mumbai India. Abstract p.88.
421		https://resvinet.org/wp-content/uploads/2024/02/Abstract-Booklet-09Feb24.2.pdf
422	12.	Ison MG, Papi A, Athan A, Feldman RG, Langley JM, Lee DG, Leroux-Roels I,
423		Martinon-Torres F, Schwarz T, van Zyl-Smit RN et al. Efficacy and Safety of
424		Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in
425		Older Adults Over 2 RSV Seasons. Clin Infect Dis. 2024 Jan 22:ciae010. doi:
426		10.1093/cid/ciae010. Online ahead of print
427	13.	Walsh EE, Falsey A, Patton M, Stacey H, Eiras DP, Jiang Q, Woodside J, Mikati T,
428		Kalinina E, Cooper D et al. Efficacy of a Bivalent RSVpreF Vaccine in Older Adults
429		beyond a First RSV Season. RSVVW ReSVINET Conference February 13-16 2024,
430		Mumbai India.Abstract p.99. https://resvinet.org/wp-
431		content/uploads/2024/02/Abstract-Booklet-09Feb24.2.pdf
432	14.	Falsey AR, Williams K, Gymnopoulou E, Bart S, Ervin J, Bastian AR, Menten J, De
433		Paepe E, Vandenberghe S, Chan EKH et al. Efficacy and safety of an Ad26.RSV.preF-
434		RSV preF protein vaccine in older adults. N Engl J Med. 2023;388:609-620
435	15.	Jenkins, V.A.; Hoet, B., Hochrein, H., De Moerlooze, L. The Quest for a Respiratory
436		Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein. Vaccines
437		2023, 11, 382. https://doi.org/10.3390/vaccines1102038
438	16.	NCT04908683. A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-
439		stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV)
440		Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60
441		Years and Older (EVERGREEN).
442		https://classic.clinicaltrials.gov/ct2/show/results/NCT04908683?term=vaccine+efficac
443		y+Janssen&cond=RSV&draw=2&rank=1

444	17. Endt K.	W. Y.	(2022)	. A recombi	nant MVA	-Based	RSV V	<i>V</i> accine	Induces	T ce	ell ar	ıd

Antibody Responses that Cooperate in the Protection Against RSV Infection. Front

446 Immunol, 10.3389/fimmu.2022.841471

- 447 18. Samy N, Reichhardt D, Schmidt D, Chen LM, Silbernagl G, Vidojkovic S et al. Safety
- 448 and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A
- randomized phase I clinical trial. Vaccine 38 (2020) 2608-2613.
- 450 <u>https://doi.org/10.1016/j.vaccine.2020.01.055</u>
- 451 19. Jordan E, Lawrence SJ, Meyer TPH, Schmidt D, Schultz S, Mueller J et al. Broad
- 452 Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel
- 453 Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine. The Journal of
- 454 Infectious Diseases® 2021;223:1062–72
- 455 20. Jordan E, Kabir G, Schultz S, Silbernagl G, Schmidt D, Jenkins VA et al. Reduced
- 456 Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge
- 457 Trial of MVA-BN-RSV Vaccine. The Journal of Infectious Diseases, Volume 228,
- 458 Issue 8, 15 October 2023, Pages 999–1011
- 459 21. World Medical Association. World Medical Association Declaration of Helsinki:
- 460 ethical principles for medical research involving human subjects. JAMA
- 461 2013;310:2191-4. doi:10.1001/jama.2013.281053
- 462 22. ICH Guideline for Good Clinical Practice E6 (R2) Step 5. Available at: ICH E6 (R2)

```
463 <u>Good clinical practice - Scientific guideline | European Medicines Agency (europa.eu)</u>
```

- 464 23. Suter M, Meisinger-Henschel C, Tzatzaris M, et al. Modified vaccinia Ankara strains
- 465 with identical coding sequences actually represent complex mixtures of viruses that
- determine the biological properties of each strain. Vaccine 2009; 27:7442–50
- 467 24. Falsey AR, Walsh EE, Osborne RH, Vandendijck Y, Ren X, Witek J, Kang D, Chan E,
- 468 Scott J, Ispas G (2021) Comparative assessment of reported symptoms of influenza,

469	respiratory syncytial virus, and human metapneumovirus infection during
470	hospitalization and post-discharge assessed by Respiratory Intensity and Impact
471	Questionnaire: Influenza and Other Respiratory Viruses 2021
472	25. US Food and Drug Administration. Guidance for industry: toxicity grading scale for
473	healthy adult and adolescent volunteers enrolled in preventive vaccine clinical
474	trials. 2007 (https://www.fda.gov/media/73679/download)
475	26. Centers for Disease Control and Prevention. (2023, March). Retrieved from RSV
476	Surveillance: https://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html
477	27. RKI SurvStat. (2023, March). Retrieved from Robert Koch Institute:
478	https://survstat.rki.de/Content/Query/Create.aspx
479	28. Committee for Medicinal Products for Human Use (CHMP). EMA/227054/2023,
480	CHMP assessment report, Arexvy. 26 April 2023
481	29. US Food and Drug Administration, Abrysvo Cinical Review Memorandum:
482	https://www.fda.gov/vaccines-blood-biologics/abrysvo
483	30. Fink Al, Klein SL. Sex and gender impact immune responses to vaccines among the
484	elderly. Physiology (Bethesda). 2015 Nov;30(6):408-16. doi:
485	10.1152/physiol.00035.2015
486	31. Chambers C, Skowronski DM, Rose C, Serres G, Winter AL, Dickinson JA, Jassem
487	A, Gubbay JB, Fonseca K, Drews SJ, Charest H, Martineau C, Petric M, Krajden M.
488	Should Sex Be Considered an Effect Modifier in the Evaluation of Influenza Vaccine
489	Effectiveness? Open Forum Infect Dis. 2018 Sep 4;5(9):ofy211. doi:
490	10.1093/ofid/ofy211. PMID: 30263903; PMCID: PMC6143149
491	32. Ursin RL, Klein SL. Sex Differences in RespiratoryViral Pathogenesis and
492	Treatments. Annu. Rev. Virol. 2021. 8:393-414

493	33. Dayananda P, Chiu C, Openshaw P Controlled Human Infection Challenge Studies
494	with RSV. Curr Top Microbiol Immunol. 2022 Jun 16. doi: 10.1007/82_2022_257.
495	Online ahead of print
496	34. Salaun B, De Smedt J, Vernhes C, Moureau A, Öner D, Bastian AR, Janssens M
497	Balla-Jhagjhoorsingh S, Aerssens J, Lambert C, Coenen S, Butler CC, Drysdale SB,
498	Wildenbeest JG, Pollard AJ, Openshaw PJM and Bont L. (2023) T cells, more than
499	antibodies, may prevent symptoms developing from respiratory syncytial virus
500	infections in older adults. Front. Immunol. 14:1260146. doi:
501	10.3389/fimmu.2023.1260146
502	35. Walsh EE, Falsey AR, Scott DA, Gurtman A, Zareba AM, Jansen KU et al. A
503	Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.
504	The Journal of Infectious Diseases® 2022;225:1357-66
505	36. Falloon J, Yu J, Esser MT, Villafana T, Yu L, Dubovsky F, Takas T et al. An
506	Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory
507	Syncytial Virus Illness in Older Adults. The Journal of Infectious Diseases®
508	2017;216:1362–70
509	37. Novavax. Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials
510	in Older Adults [Internet]. 2022 [cited 2022Nov10]. Available from:
511	https://ir.novavax.com/2016-09-25-Novavax-Announces-Topline-RSV-F-Vaccine-
512	Data-from-Two-Clinical-Trials-in-Older-Adults
513	38. US Food and Drug Administration, Jynneos® package insert. Available at
514	https://www.fda.gov/vaccines-blood-biologics/jynneos
515	39. Nave, L.; Margalit, I.; Tau, N.; Cohen, I.; Yelin, D.; Lienert, F.; Yahav, D.
516	Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine-A

- 517 Systematic Review and Meta-Analysis of Randomized Controlled Trials. Vaccines
- 518 2023, 11, 1410. https://doi.org/10.3390/ vaccines110914100

519 Acknowledgments

- 520 We thank the participants of the clinical study, the clinical site investigators and their staff
- 521 and the ICON clinical research team.
- 522 **Financial support.** This work was supported by Bavarian Nordic A/S.

Table 1. Demographics and baseline characteristics of participants (FAS)

	MVA-BN-RSV (N=9160)	Placebo (N=9188)
Age (years)	70.4 (5.70)	70 5 (5 00)
Mean (SD)	70.4 (5.78)	70.5 (5.83)
Age Group, n (%)		
60 to 64	931 (10.2)	933 (10.2)
65 to 74	6166 (67.3)	6164 (67.1)
75 to 84	1889 (20.6)	1903 (20.7)
>= 85	174 (1.9)	188 (2.0)
Female sex, n (%)	4606 (50.3)	4680 (50.9)
Race, n (%)		
White	7786 (85.0)	7794 (84.8)
Black or African American	1185 (12.9)	1202 (13.1)
Other	189 (2.1)	192 (2.1)
Ethnicity, n (%)		
Hispanic or Latino	2605 (28.4)	2659 (28.9)
Not Hispanic or Latino	6464 (70.6)	6432 (70.0)
Other	91 (1.0)	97 (Ì.1)
Body mass index		
Mean (SD)	29.44 (6.094)	29.27 (5.958)
Tilburg Frailty Indicator Group, n (%)		
Non-frail (Total Score <5)	7980 (87.1)	7992 (87.0)
Frail (Total Score >=5)	966 (10.5)	995 (10.8)
Not Reported	214 (2.3)	201 (2.2)
Underlying chronic condition, n (%)		
Any chronic condition	6061 (66.2)	6145 (66.9)
Chronic Lung Diseases	1093 (11.9)	1192 (13.0)́
Chronic Cardiac Diseases	5725 (62.5)	5760 (62.7)
Geographic Region, n (%)		
USA	8445 (92.2)	8468 (92.2)
Germany	715 (7.8)	720 (7.8)

The FAS was the primary analysis set for efficacy assessments and included participants who were randomized to any treatment arm and received the study vaccination; SD: standard deviation.

Table 2. Humoral immune response at baseline and 14 days post-vaccination (serum subset)

	n	MVA-BN-RSV (N=309)	n	Placebo (N=317)			
RSV subtype A neutralizing antibodies							
GMT at baseline (95%CI)	306	275.1 ([249.4, 303.4)	314	310.6 (280.5, 343.9)			
GMT at Day 15 (95%CI)	295	482.3 (436.9, 532.5)	290	307.7 (276.5, 342.4)			
GMFI (95%CI)	292	1.74 (1.62, 1.86)	287	1.0 (0.95, 1.05)			
RSV subtype B neutralizin	g antik	podies					
GMT at baseline (95%CI)	306	289.5 (251.5, 333.1)	314	336.5 (292.1, 387.5)			
GMT at Day 15 (95%CI)	295	475.3 (419.7, 538.3)	290	307.6 (265.4, 356.5)			
GMFI (95%CI)	292	1.68 (1.56, 1.81)	287	0.95 (0.91, 0.99)			
RSV IgG							
GMT at baseline (95%CI)	306	1510.6 (1386.4, 1646.0)	314	1590.1 (1468.3, 1722.0)			
GMT at Day 15 (95%CI)	295	4335.5 (3963.7, 4742.2)	290	1562.9 (1440.5, 1695.6)			
GMFI (95%CI)	292	2.87 (2.65, 3.10)	287	0.99 (0.96, 1.02)			
RSV IgA							
GMT at baseline (95%CI)	306	1147.5 ([1019.8,	314	1060.3 (937.7, 1198.9)			
		1291.1)		· · · · ·			
GMT at Day 15 (95%CI)	295	4984.2 (4329.5, 5737.9)	290	1060.3 (937.7, 1198.9)			
GMFI (95%CI)	292	4.33 (3.93, 4.76)	287	1.0 (0.96, 1.03)			

CI: confidence interval; GMFI: geometric fold increase; GMT: geometric mean titre;


Ig: immunoglobulin; n: number in analysis

Table 3. Frequency of Unsolicited Adverse Events and SAEs after vaccination (SS)

	MVA-BN-RSV (N=9389)	Placebo (N=8959)						
Unsolicited Adverse Events (within 28 days after vaccination)								
All, n (%)	607 (6.5)	581 (6.5)						
Grade ≥3, n (%)	71 (0.8)	45 (0.5)						
Related, n (%)	103 (1.1)	50 (0.6)						
Grade≥3 & Related, n (%)	11 (0.1)	2 (<0.05)						
Serious Adverse Events (during the entire study period)								
All, n (%)	517 (5.5)	422 (4.7)						
Related, n (%)	7 (0.1)	5 (0.1)						
Fatal, n (%)	41 (0.4)	34 (0.4)						

The safety set was the primary analysis set for safety evaluation; it included participants who received any MVA-BN-RSV vaccine or placebo. Related: thought to be related to study vaccination or placebo by the investigator.

Figure 1. Enrolment and disposition of participants in the analyses



a. Nineteen participants were randomized but not vaccinated; these included 12 additional participant withdrawals, 1 discontinuation of a noncooperative participant, 4 discontinuations after technical difficulties, 1 protocol violation, and 1 discontinuation for ineligibility (participation in another study).


b. Treatment allocation based on the (first) randomization; 5 participants received a different treatment than the one they were randomized to (4 participants randomized to MVA-BN-RSV received placebo and 1 participant randomized to placebo received MVA-BN-RSV instead).

c. There were 5 additional deaths reported in the study: 2 deaths were reported after participant withdrawal and 1 after study completion. The other 2 participants were dual/multiple enrollers and were reported as withdrawn or discontinued from their first enrolment; their deaths were reported with a later enrolment.


d.One participant in each treatment group confirmed consent for durability follow-up but did not have any activity and therefore were not counted as having discontinued durability follow-up

Figure 2. Cumulative incidence of RSV-associated LRTD and RSV-related ARD (FAS)


A RSV-associated LRTD with ≥ 3 symptoms



B RSV-associated LRTD with ≥ 2 symptoms




C RSV-associated ARD



This Figure presents the cumulative incidence of RSV–associated lower respiratory tract disease with at least 3 symptoms (Panel A), with at least 2 symptoms (Panel B) and RSV-associated acute respiratory disease (Panel C). The analysis included PCR-confirmed RSV-associated LRTD or ARD with onset at least 14 days after vaccination (full analysis set). The full analysis set was the primary analysis set for efficacy assessments; it consisted of participants who were randomized to any treatment arm and received the study vaccination.

Figure 3. Severity of RSV-associated LRTD symptoms based on RiiQ scores



This graph shows the total respiratory and systemic symptom severity among participants with RT-PCR–confirmed RSV-associated acute respiratory disease as measured with the Respiratory Infection Intensity and Impact Questionnaire (RiiQ); higher area-under-the-curve (AUC) values indicate greater symptom severity. The top and bottom of the box indicate the third and first quartiles, the whiskers indicate the range (minimum, maximum), the horizontal line inside the box indicates the median; the star indicates the mean value.





Figure 4a. Frequency of Solicited Local Adverse Events after vaccination (SS)

Figure 4b. Frequency of Solicited Systemic Adverse Events after vaccination (SS)



The safety set was the primary analysis set for safety evaluation; it included participants who received any MVA-BN-RSV vaccine or placebo. MVA: MVA-BN-RSV group; Plac: placebo group; Percentage: percentage of participants reporting an AE. In Figure 4a, solicited local AEs were pain, erythema, swelling, induration and pruritus reported at the injection site during the 7 days following vaccination. In Figure 4b, solicited systemic AEs were pyrexia, headache, myalgia, chills, nausea and fatigue reported during the 7 days following vaccination.

Subgroup Analyses by Sex for Table 15.2.5.1.1(2): Systemic Humoral Immunogenicity - Antibody Titers (Immunogenicity Analysis Set - Serum Subset)

Supplementary Table 1. Occurrence and Vaccine Efficacy of LRTD based on RiiQ Responses

Number of LRTD Symptoms in RiiQ	MVA-BN-RSV N=9160	Placebo N=9188	Vaccine Efficacy % (95% CI)		
	n events	n events			
≥3 mild symptoms	18	51	64.8 (39.7; 79.4)		
≥2 mild symptoms	31	74	58.1 (36.3; 72.5)		
≥3 moderate symptoms	6	19	68.5 (21.1; 87.4)		
≥2 moderate symptoms	10	45	77.8 (56.0; 88.8)		

LRTD: lower respiratory tract disease; RiiQ: Respiratory Intensity and Impact Questionnaire; CI: confidence interval

Supplementary Table 2. Vaccine Efficacy against RSV-associated LRTD and ARD – Analysis per Sex (Full Analysis Set)

	Ν	MVA-	BN-RSV	Ν	Pla	cebo	Hazard	Vaccine
		n events (%)	Censor, n (%)		n events (%)	Censor, n (%)	Ratio (95% CI)	Efficacy % (95% CI)
LRTD ≥ 3	sympto	oms						
Male	4554	10 (0.2)	4544 (99.8)	4508	7 (0.2)	4501 (99.8)	1.415	-41.5
							(0.539, 3.718)	(-271.8, 46.1)
Female	4606	2 (<0.05)	4604	4680	14 (0.3)	4666 (99.7)	0.145	85.5
			(100.0)				(0.033, 0.636)	(36.4, 96.7)
LRTD ≥ 2	sympto	oms						
Male	4554	17 (0.4)	4537 (99.6)	4508	27 (0.6)	4481 (99.4)	0.623	37.7
							(0.340, 1.144)	(-14.4, 66.0)
Female	4606	8 (0.2)	4598 (99.8)	4680	34 (0.7)	4646 (99.3)	0.238	76.2
							(0.110, 0.514)	(48.6, 89.0)
ARD								
Male	4554	28 (0.6)	4526 (99.4)	4508	33 (0.7)	4475 (99.3)	0.841	15.9
			. ,				(0.508, 1.391)	(-39.1, 49.2)
Female	4606	14 (0.3)	4592 (99.7)	4680	49 (1.0)	4631 (99.0)	0.288	71.2
		. ,	. ,		. ,	. ,	(0.159, 0.522)	(47.8, 84.1)

LRTD: lower respiratory tract disease; ARD: Acute respiratory disease; CI: confidence interval

Subgroup Analyses by Sex for Table 15.2.5.1.1(2): Systemic Humoral Immunogenicity - Antibody Titers (Immunogenicity Analysis Set - Serum Subset)

Supplementary Table 3. Vaccine efficacy against RSV-associated LRTD – post hoc analysis per sex, per exact number of symptoms (FAS)

Number of LRTD	Sex	MVA-BN-RSV	Placebo	Vaccine Efficacy
Symptoms		n	n	% (95% CI)
≤ 1 symptom	Female	6	15	59.7 (-4.0; 84.3)
	Male	11	6	-81.4 (-390.5; 32.9)
2 symptoms	Female	6	20	69.7 (24.5; 87.8)
	Male	7	20	65.3 (18.0; 85.3)
≥ 3 symptoms	Female	2	14	85.5 (36.4, 96.7)
	Male	10	7	-41.5 (-271.8, 46.1)

LRTD: lower respiratory tract disease; CI: confidence interval

Subgroup Analyses by Sex for Table 15.2.5.1.1(2): Systemic Humoral Immunogenicity - Antibody Titers (Immunogenicity Analysis Set - Serum Subset)

					GMT GN			GMFI
Sex	Parameter	Group	Visit	Ν	GMT	(95% CI)	GMFI	(95% CI)
Female	RSV IgA (GMT)	MVA-BN-RSV	Baseline	162	960.2	(825.4; 1117.1)		
			Day 15	157	4347.1	(3609.0; 5236.1)	4.51	(3.94; 5.16)
		Placebo	Baseline	147	1015.2	(851.0; 1211.2)		
			Day 15	142	992.1	(832.6; 1182.1)	1.01	(0.96; 1.06)
	RSV IgG (GMT)	MVA-BN-RSV	Baseline	162	1370.8	(1211.3; 15510.3)		
			Day 15	157	4069.3	(3560.3; 4651.1)	2.95	(2.64; 3.29)
		Placebo	Baseline	147	1448.7	(1288.3; 1629.0)		
			Day 15	142	1407.6	(1253.1; 1581.1)	0.98	(0.95; 1.03)
	RSV Type A	MVA-BN-RSV	Baseline	162	236.4	(204.6; 273.0)		
	Neutralizing GMT		Day 15	157	423.9	(369.9; 485.8)	1.75	(1.59; 1.93)
		Placebo	Baseline	147	283.5	(248.6; 323.4)		
			Day 15	142	271.3	(234.1; 314.4)	0.99	(0.93; 1.05)
	RSV Type B	MVA-BN-RSV	Baseline	162	278.3	(229.5; 337.5)		
	Neutralizing GMT		Day 15	157	429.6	(360.3; 512.2)	1.58	(1.44; 1.73)
		Placebo	Baseline	147	267.0	(219.8; 324.4)		
			Day 15	142	255.8	(209.5; 312.4)	0.96	(0.90; 1.03)
Male	RSV IgA (GMT)	MVA-BN-RSV	Baseline	144	1402.0	(1170.7; 1679.1)		
			Day 15	138	5823.3	(4703.6; 7209.5)	4.13	(3.60; 4.74)
		Placebo	Baseline	167	1155.8	(980.9; 1334.6)		
			Day 15	148	1130.1	(949.9; 1344.6)	0.99	(0.94; 1.04)
	RSV IgG (GMT)	MVA-BN-RSV	Baseline	144	1685.1	(1499.1; 1894.1)		
			Day 15	138	4659.6	(4143.6; 5239.8)	2.78	(2.49; 3.10)
		Placebo	Baseline	167	1726.0	(1549.1; 1923.2)		
			Day 15	148	1727.9	(1542.9; 1935.1)	1.00	(0.96; 1.04)
	RSV Type A	MVA-BN-RSV	Baseline	144	326.3	(287.5; 370.2)		
	Neutralizing GMT		Day 15	138	558.6	(484.7; 643.7)	1.71	(1.56; 1.88)
		Placebo	Baseline	167	336.5	(288.7; 392.2)		
			Day 15	148	347.1	(297.6; 404.9)	1.01	(0.93; 1.09
	RSV Type B	MVA-BN-RSV	Baseline	144	302.6	(245.9; 372.3)	-	
	Neutralizing GMT		Day 15	138	533.3	(447.5; 635.7)	1.80	(1.61; 2.02)
		Placebo	Baseline	167	412.4	(337.7; 503.5)		
			Day 15	148	367.0	(296.1; 455.0)	0.94	(0.90; 1.00)

Supplementary Table 4. Humoral immune response at baseline and 14 days post-vaccination (serum subset) - per sex analysis

GMT: geometric mean titer; GMFI: Geometric mean fold-increase; CI: confidence interval